0.9031

2.18% -0.0222

Chimerix Inc (CMRX)

Overview News Price History Option Chain Discussions Forecast

Chimerix Inc stock is currently priced at $0.9031, with a 24-hour trading volume of 68,449. It has seen a -2.18% decreased in the last 24 hours and a -9.47% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $0.9212 pivot point. If it approaches the $0.9024 support level, significant changes may occur.

Previous Close:

$0.9253

Open:

$0.93

24h Volume:

68,449

Market Cap:

$80.92M

Revenue:

$324.00K

Net Income/Loss:

$-82.10M

P/E Ratio:

0.4384

EPS:

2.06

Net Cash Flow:

$-69.18M

1W Performance:

+0.12%

1M Performance:

-9.47%

6M Performance:

-4.73%

1Y Performance:

-23.30%

1D Range:

$0.9031

$0.93

52W Range:

$0.88

$1.57

Chimerix Inc Stock (CMRX) Company Profile

Name

Chimerix Inc

Sector

Healthcare (1203)

Industry

Biotechnology (685)

Phone

919-806-1074

Address

2505 Meridian Parkway, Suite 100, Durham, NC

Employee

Twitter

@chimerix

Next Earnings Date

2024-05-02

Latest SEC Filings

CMRX's Discussions on Twitter

Chimerix Inc Stock (CMRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-07-22	Initiated	CapitalOne	Overweight
Apr-29-21	Initiated	Maxim Group	Buy
Apr-23-21	Resumed	Cowen	Outperform
Mar-31-21	Initiated	Jefferies	Buy
Mar-31-21	Initiated	Wedbush	Outperform
Feb-14-18	Downgrade	JP Morgan	Neutral → Underweight
Feb-02-18	Initiated	H.C. Wainwright	Buy
Aug-09-16	Reiterated	FBR Capital	Mkt Perform
Feb-23-16	Downgrade	Barclays	Overweight → Equal Weight
Feb-23-16	Reiterated	FBR Capital	Mkt Perform
Feb-23-16	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Feb-22-16	Downgrade	Citigroup	Buy → Neutral
Dec-29-15	Downgrade	JP Morgan	Overweight → Neutral
Dec-28-15	Downgrade	FBR Capital	Outperform → Mkt Perform
Dec-28-15	Reiterated	Piper Jaffray	Overweight
Dec-17-15	Initiated	UBS	Buy
Oct-05-15	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Sep-03-15	Initiated	Citigroup	Buy
Aug-18-15	Initiated	FBR Capital	Outperform
Aug-06-15	Reiterated	Brean Capital	Buy
May-11-15	Reiterated	Brean Capital	Buy
Mar-04-15	Initiated	Barclays	Overweight
Feb-12-15	Reiterated	Stifel	Buy
Dec-31-14	Reiterated	Brean Capital	Buy
Jul-08-14	Resumed	Brean Capital	Buy

View All

Chimerix Inc Stock (CMRX) Latest News

Chimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024

GlobeNewswire Inc.

Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

Chimerix to Report Fourth Quarter and Year End 2023 Financial Results and Provide an Operational Update on February 29, 2024

GlobeNewswire Inc.

Chimerix Inc Stock (CMRX) Financials Data

Chimerix Inc (CMRX) Revenue 2024

CMRX reported a revenue (TTM) of $324.00 thousand for the quarter ending December 31, 2023, a -99.04% decline year-over-year.

Chimerix Inc (CMRX) Net Income 2024

CMRX net income (TTM) was -$82.09 million for the quarter ending December 31, 2023, a -147.68% decrease year-over-year.

Chimerix Inc (CMRX) Cash Flow 2024

CMRX recorded a free cash flow (TTM) of -$69.18 million for the quarter ending December 31, 2023, a -47.38% decrease year-over-year.

Chimerix Inc (CMRX) Earnings per Share 2024

CMRX earnings per share (TTM) was -$0.93 for the quarter ending December 31, 2023, a -147.45% decline year-over-year.

Chimerix Inc Stock (CMRX) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
LaSpaluto Michelle	CHIEF FINANCIAL OFFICER	Feb 14 '24	Sale	1.04	1,940	2,023	110,999
Andriole Michael T.	PRESIDENT AND CEO	Feb 14 '24	Sale	1.04	1,744	1,809	447,021
MIDDLETON FRED A	Director	Nov 17 '23	Buy	0.96	17,295	16,522	100,000
MIDDLETON FRED A	Director	Nov 10 '23	Buy	0.92	2,705	2,489	82,705
Jakeman David	VP of Finance and Accounting	Sep 28 '23	Sale	0.99	3,610	3,584	133,142
MIDDLETON FRED A	Director	Sep 25 '23	Buy	0.98	20,000	19,636	80,000
Andriole Michael T.	Chief Business Officer and CFO	May 18 '23	Buy	1.14	51,700	59,150	357,015
Sherman Michael A.	Chief Executive Officer	May 12 '23	Buy	1.12	87,000	97,652	87,000
DEMSKI MARTHA J	Director	May 10 '23	Buy	1.11	18,000	19,980	72,055
Meyer Robert J.	Director	May 08 '23	Buy	1.14	8,750	9,975	35,150

Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients. It is also developing CMX521, a nucleoside that is in Phase I clinical trials for the treatment and prevention of norovirus; and CMX157, a nucleoside analog, which is in Phase II clinical trials to treat HIV and hepatitis B virus infection. The company has license agreements with ContraVir Pharmaceuticals for the development and commercialization of CMX157 for various antiviral indications; and Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.